Strategic Manufacturing Partner Position SpectronRx as a preferred radiopharmaceutical CDMO/CMO for late-stage clinical and early commercial programs, leveraging FDA and EMA inspection credibility and a robust QA program to de-risk manufacturing and tech transfer. The ability to handle multiple therapeutic and diagnostic isotopes and provide labeling services enables clients to consolidate supply and shorten time-to-market. The recent Plus Therapeutics collaboration demonstrates the capacity to manage complex technology transfers at scale.

Isotope Portfolio Edge Offer customers a one-stop source for a broad set of isotopes and radiolabeling capabilities, reducing supplier complexity and supply risk across development and commercialization. With experience across Lu-177, Ac-225, I-131, I-124, In-111, Zr-89, Cu-64 and F-18, SpectronRx supports both diagnostic imaging and therapeutic programs.

Growth Financing Signal Recent institutional financing underscores capacity to invest in expansion of manufacturing capabilities, facilities, and isotope production. This signals readiness to take on larger programs and new isotope projects, presenting opportunities for capacity partnerships and co-development arrangements.

Proven Collaboration Network A track record of partnerships with biotech and pharma players such as ARTBIO, Y-mAbs, Global Morpho Pharma, and Plus Therapeutics shows ability to execute development collaborations, tech transfers, and long-term supply agreements, making SpectronRx a low-risk partner for new radiopharmaceutical programs.

Regulatory Edge Operating under FDA and EMA oversight with validated quality programs and approved drugs, SpectronRx offers regulatory maturity and GMP-like reliability that can accelerate audits, filings, and scale-up for sponsors seeking compliant radiopharmaceutical manufacturing.